Response to post-axitinib treatment in patients with metastatic renal cell carcinoma

BMC Cancer

Research Article

Laura S. Wood¹  Brian I. Rini¹  Jorge A. Garcia¹  Housam Haddad¹  Paul Elson¹  Namita Chittoria²  Eric Jonasch³  Nizar M. Tannir³  Robert Dreicer⁴ 

[1] Cleveland Clinic Taussig Cancer Center, 9500 Euclid Ave., Cleveland, OH, USA;Cleveland Clinic Taussig Cancer Center, 9500 Euclid Ave., Cleveland, OH, USA;Veteran Affairs Medical Center, 800 Irving Avenue, 13210, Syracuse, NY, USA;University of Texas M. D. Anderson Cancer Center, Houston, TX, USA;University of Virginia, 1240 Lee St., Charlottesville, VA, USA;

关键词: Renal cell carcinoma;    Axitinib;    Sunitinib;    VEGF inhibitors;    mTOR inhibitors;    Predictive biomarkers;   

DOI  :  10.1186/s12885-016-2282-5

 received in 2015-06-18, accepted in 2016-03-15,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundAxitinib is a potent inhibitor of the vascular endothelial growth factor (VEGF) receptor family with clinical activity in patients with metastatic renal cell carcinoma (mRCC). Given this biochemical potency, the clinical activity of subsequent treatment with targeted therapies in patients progressing on axitinib is of interest.MethodsPatients with advanced renal cell carcinoma of any pathologic subtype treated with at least one cycle (four weeks) of axitinib followed by at least one subsequent targeted therapy were investigated in a retrospective analysis. Patient characteristics, duration of treatment and clinical outcomes were analyzed for axitinib and each subsequent line of therapy by Response Evaluation Criteria in Solid Tumors (RECIST).ResultsTwenty-five mRCC patients who received at least one approved targeted agent following axitinib were identified. Eight percent of patients achieved a partial response (one patient each to sunitinib and pazopanib) and 42 % had a best response of stable disease to the first therapy after axitinib. The estimated median duration of therapy was 4.4 months (range, 0.2–27.5+). Twelve patients received a second post-axitinib targeted therapy. Six out of 11 evaluable patients (55 %) had a best response of SD. The estimated median duration of treatment was 4.8 months (range, 0.7–19.1+).ConclusionObjective responses and stable disease is observed to post-axitinib targeted therapies and prospective studies are needed for validating role of predictive biomarkers.

【 授权许可】

CC BY   
© Chittoria et al. 2016